Nephrogenic fibrosing dermopathy risk factors
|
Nephrogenic fibrosing dermopathy Microchapters |
|
Differentiating Nephrogenic fibrosing dermopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Nephrogenic fibrosing dermopathy risk factors On the Web |
|
American Roentgen Ray Society Images of Nephrogenic fibrosing dermopathy risk factors |
|
Directions to Hospitals Treating Nephrogenic fibrosing dermopathy |
|
Risk calculators and risk factors for Nephrogenic fibrosing dermopathy risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Risk Factors
Risk Factors
Although risk factors for NFD have not been studied extensively, possible correlations with severity of renal failure, thrombotic episodes, edema, and vascular procedures have been reported [1][2][3]. Recently, medication exposures such as erythropoietin and gadolinium-containing contrast agents have been identified as potential risk factors for NFD [4] [5] In May 2006, the Danish Medicines Agency reported 25 cases of NFD diagnosed in Europe among patients with recent exposure to gadolinium-containing contrast. In response, the Food and Drug Administration (FDA) issued a public health advisory in June 2006 regarding the use of these contrast agents ([gadopentetate dimeglumine (Magnevist), gadobenate dimeglumine (MultiHance), gadodiamide (Omniscan), gadoversetamide (OptiMARK), gadoteridol (ProHance)] in patients with moderate to end-stage renal disease [6]. As of December 25, 2006, the FDA MedWatch system had received 90 reports of NFD possibly related to gadolinium-containing contrast agents. Worldwide, over 200 cases have been reported, according to the FDA. NSF/NFD is a debilitating and sometimes fatal disease.
References
- ↑ Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15:785-90.
- ↑ Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139: 903-6.
- ↑ Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 2003;143: 678-81
- ↑ Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-62.
- ↑ Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006;145:234-5.
- ↑ Food and Drug Administration. Public health advisory: gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. Available at http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm.